Acumen reports Q3 EPS (44c), consensus (68c)

“We continued our strong operational progress throughout the third quarter, both clinically, with our ongoing Phase 2 trial of sabirnetug, and non-clinically, with the advancement of our Enhanced Brain Delivery program. Our goal remains clear: to deliver meaningful innovation for patients,” said Daniel O’Connell, CEO. “We remain focused on translating cutting-edge science into novel medicines with the greatest potential to benefit patients, while deploying capital with the goal of maximizing shareholder value. We anticipate non-clinical data in early 2026 will inform the direction of our EBD strategy and ALTITUDE-AD Phase 2 topline results in late 2026 will provide true insight into the role AbetaOs play in Alzheimer’s disease.”